Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study.

	Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study.
	Lai, Shuzhen ; Chen, Yuan Yuan Yuan ; Li, Peijing ; Jiang, Fagui ; Liu, Xiaohui ; Tao, Changjuan ; Huang, Jing ; Tang, Yiqiang ; Liu, Zhigang ; Shen, Guoping
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-06-01
卷号	40
ISSN号	0732-183X
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000863680302759
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129877]
专题	中国科学院合肥物质科学研究院
作者单位	1.Maoming Peoples Hosp, Maoming, Peoples R China 2.Nanchang Univ, Canc Hosp, Nanchang, Peoples R China 3.Sun Yat Sen Univ, Ctr Canc, Affiliated Hosp 5, Zhuhai, Peoples R China 4.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China 5.Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China 6.Shantou Univ, Guangdong YueBei Peoples Hosp, Shaoguan, Peoples R China 7.Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China 8.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 9.Kecheng Dist Peoples Hosp, Quzhou, Peoples R China 10.Self, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Lai, Shuzhen,Chen, Yuan Yuan Yuan,Li, Peijing,et al. Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Lai, Shuzhen.,Chen, Yuan Yuan Yuan.,Li, Peijing.,Jiang, Fagui.,Liu, Xiaohui.,...&Liu, Guihong.(2022).Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Lai, Shuzhen,et al."Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).